Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative.
Charles J DuntonMegan Leigh HutchcraftRowan G BullockLesley E NorthropFrederick Rand UelandPublished in: Diagnostics (Basel, Switzerland) (2021)
As a standalone test, CA125 misses a significant number of ovarian malignancies that can be detected by OVA1. This is particularly important for premenopausal women and early-stage cancers, which have a much better long-term survival than late-stage malignancies. Using OVA1 in the setting of a normal serum CA125 can help identify at-risk ovarian tumors for referral to a gynecologic oncologist, potentially improving overall survival.
Keyphrases
- early stage
- protein kinase
- sentinel lymph node
- primary care
- polycystic ovary syndrome
- postmenopausal women
- breast cancer risk
- type diabetes
- adipose tissue
- radiation therapy
- squamous cell carcinoma
- lymph node
- metabolic syndrome
- insulin resistance
- endometrial cancer
- real time pcr
- quantum dots
- pregnancy outcomes
- locally advanced
- early breast cancer